Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial
Hyun Yong Jin(Scripps Research Institute), Franck Morschhauser(Hôpital Claude Huriez), Rosemary Harrup(University of Tasmania), Yanwen Jiang, Luca Laurenti(Sapienza University of Rome), Maria Thadani‐Mulero(Roche (United Kingdom)), Michelle Boyer(Amgen (United States)), Roberto Marasca(University of Modena and Reggio Emilia), Paolo Sportoletti(University of Perugia), Stephen P. Mulligan(Royal North Shore Hospital), Emmanuelle Ferrant(Hôpital Lyon Sud), Stephen Opat(Monash Health), Adalberto Ibatici(Ospedale Policlinico San Martino), Oscar Cazarez(Genentech), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Archie Egginton(Roche (United Kingdom)), Luis Felipe Casado Montero(Complejo Hospitalario Universitario de Toledo)
Cited by 0
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907